Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07488234

Impact of a Glaucoma Awareness Program on Treatment Adherence

Glaucoma is a leading cause of irreversible blindness worldwide, with a higher burden in low- and middle-income countries such as Nepal, where public awareness and treatment adherence remain poor. Lifelong adherence to treatment is important to prevent disease progression but still non adherence remains common.

This is a mixed method study which aims to evaluate the effectiveness of structured glaucoma awareness program in improving treatment adherence among glaucoma patients attending a tertiary eye hospital in Nepal. Quantitative assessment will measure changes in treatment adherence using Medication Adherence Scale at baseline and three months post intervention. A qualitative component will explore participants' perceptions of glaucoma program and suggestions for improvement through semi-structured interviews.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

About this study

A mixed method interventional study will be conducted to assess the impact of a structured glaucoma awareness program on treatment adherence among the glaucoma follow-up patients attending a tertiary eye hospital in Nepal. The total study duration will be 10 months including preparation, participant recruitment, awareness program and follow up after 3 months, data analysis and reporting.

The primary objective of this study is to compare the treatment adherence scores of glaucoma patients before and three months after participation in the glaucoma awareness program.

The secondary objective is to qualitatively explore the participants' perceptions of the awareness program, identify barriers to treatment adherence and get the suggestions for improving patient education.

Patient ≥18 years with pre-existing diagnosis of glaucoma attending routine follow up visits will be invited to participate. All the eligible patients who meet the inclusion criteria will be selected. A formal sample size calculation will be performed prior to recruitment. Based on prior literature, a target sample size of approximately 60 participants is anticipated to provide adequate statistical power. After obtaining a written informed consent, participants will complete a baseline self-reported questionnaire assessing demographics and treatment adherence using the validated medication adherence scale.

Participants will then attend a structured 30-minute glaucoma awareness program consisting of a PowerPoint presentation covering foundational concepts of glaucoma and related risk factors, disease progression, and the importance of treatment adherence. An illustrated one-page informational leaflet in simple Nepali will be distributed to all participants. An interactive question-and-answer session will be conducted to respond to queries. To ensure the program is inclusive and accessible for glaucoma patients with visual impairment, power point slides and leaflets will use large fonts, high contrast and simple illustration. Key messages and visual content will be reinforced verbally. Participants will be encouraged to ask questions and clarification will be provided as needed.

At three months post-intervention, same participants will be contacted by telephone by the principle investigator to reassess treatment adherence using the same validated tools. Quantitative data will be analyzed using paired statistical tests to compare pre- and post-intervention outcomes.

A selected sub sample of approximately 8 - 10 participants will undergo semi-structured qualitative interviews three months after the awareness program, to explore their experiences with the awareness program, perceived benefits, barriers to implementing learned behaviors, and recommendations for improvement. Interviews will be audio-recorded, transcribed verbatim, translated into English, and analyzed using thematic analysis.

The study will receive approval from NHRC. Confidentiality will be maintained through anonymization of data, and participants may withdraw at any time without impact on their medical care.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

- Adults aged ≥18 years

  • Diagnosed with glaucoma
  • Attending follow-up at the study hospital
  • Able to provide informed consent
  • Able to communicate in Nepali language

Exclusion criteria

Individuals with cognitive impairments; healthcare professionals; individuals who have participated in a formal glaucoma education program in the past year.

Treatment and study plan

Glaucoma awareness and patient education program

Other

Glaucoma awareness educational package: Educational session, information leaflets, interactive discussions.

This study involves a behavioral/educational intervention only. No drugs, devices, or procedures are introduced as part of the study intervention. Participants continue their routine standard-of-care glaucoma treatment as prescribed by their treating ophthalmologist.

No investigational drugs or devices are used as part of this study. Participants continue their usual prescribed anti-glaucoma medications as part of routine clinical care. The study intervention consists solely of a structured educational and awareness program.

Primary outcomes

  1. Treatment adherence scores

    Time frame: 10 months

    Treatment adherence will be assessed using Glaucoma Treatment Compliance Assessment Tool- Short Form(GTCAT-S).

    Treatment adherence will be assessed using the Glaucoma Treatment Compliance Assessment Tool-Short Form (GTCAT-S), a validated self-administered questionnaire designed to evaluate adherence behavior, beliefs, and barriers among glaucoma patients. Approval for the use of GTCAT-S in this study has been obtained from the GTCAT development team.

    Scale Details:

    • Each item is scored on a 5-point Likert scale: 1 = Disagree a lot to 5 = Agree a lot
    • Patients classified
    • Low adherence: <75%
    • High adherence: ≥75%
    • Direction:

    Higher scores indicate better treatment adherence

Secondary outcomes

  1. Participants' perceptions of the glaucoma awareness program assessed using semi-structured interview guide

    Time frame: 3 months post-intervention

    Participants' perceptions of the glaucoma awareness program, including perceived usefulness, clarity of information, behavioral impact, barriers to treatment adherence, and suggestions for improvement, will be assessed through semi-structured in-depth interviews conducted at three months post-intervention.

    Assessment Method:

    • Semi-structured interview guide developed by the research team
    • Open-ended questions exploring:
    • Understanding of glaucoma
    • Perceived benefits of the awareness program
    • Barriers to applying learned information
    • Suggestions for improving patient education
    • Interviews will be audio-recorded, transcribed verbatim, translated into English, and analyzed using thematic analysis Scale Used: Not applicable (qualitative assessment; no numerical scoring)

Study contacts

Contact information is provided by the study sponsor or research team.

Dr. Deekshya Malla

CONTACT

[email protected]

+977 9851182007

Sponsors and collaborators

Lead sponsor

Seva Canada Society

Other

Collaborators

  • Pragyaan Sustainable Health Outcomes Foundation
  • Reiyukai Eiko Masunaga Eye Hospital (REMEH)

Registry information

Official study title

Assessing the Impact of a Structured Glaucoma Awareness Program on Treatment Adherence Among Glaucoma Patients at Tertiary Eye Hospital in Nepal

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Mar 23, 2026
Registry last updated
Mar 23, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.